Related Experiment Video
Updated: Jun 14, 2025
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence
Joanna Narbutt1, Zofia Jakubczak2, Paulina Wasiewicz-Ciach2
1Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, 90-419 Lodz, Poland.
Insights
Etanercept effectively treated plaque psoriasis in children, significantly improving skin severity and quality of life. This biologic therapy demonstrated a favorable safety profile in pediatric patients.
Area of Science:
- Pediatric Dermatology
- Immunology
- Inflammatory Diseases
Background:
- Psoriasis affects 1% of children, impacting their quality of life.
- Etanercept, a TNF-α inhibitor, is used in pediatric psoriasis treatment.
- Plaque-type psoriasis in children requires effective and safe therapeutic options.
Purpose of the Study:
- To evaluate the efficacy of etanercept in pediatric plaque psoriasis.
- To assess the safety and tolerability of etanercept in children.
- To determine the treatment outcomes using PASI, BSA, and CDLQI.
Main Methods:
- Study included 43 pediatric patients with plaque psoriasis.
- Treatment outcomes assessed via Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Children's Dermatology Life Quality Index (CDLQI).
- Primary endpoint: achieving at least PASI75 at week 16.
Main Results:
- At week 16, 79.1% of patients achieved PASI 75, and 46.5% achieved PASI 90.
- Significant reductions observed in mean BSA (22.3% to 3.5%) and CDLQI (17.4 to 5.4).
- Etanercept demonstrated high efficacy in improving psoriasis severity and quality of life.
Conclusions:
- Etanercept is an effective treatment for pediatric plaque psoriasis.
- The safety and tolerability profile of etanercept is favorable in children.
- Etanercept significantly improves health-related quality of life in pediatric patients.
Abstract:
Background: Psoriasis is a chronic, multisystemic, inflammatory disease affecting approximately 1% of children and significantly reducing their health-related quality of life. Etanercept is a biologic fusion protein-blocking TNF-α and belongs to one of the biologics used among the children population. The purpose of this study was to assess the effectiveness and safety profile of etanercept in paediatric patients with plaque-type psoriasis. Material and methods: The outcome of the treatment was evaluated based on Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Children's Dermatology Life Quality Index (CDLQI). Achievement of at least PASI75 at week 16 was assessed as an adequate response to therapy, which was the primary endpoint. Results: Forty-three paediatric patients were included in the study, 24 females and 19 males. The average age at inclusion into our study was 13 years. At baseline, the mean PASI score, BSA, and CDLQI were 16.3 ± 6.5, 22.3 ± 12.2%, and 17.4 ± 5.3, respectively. At week 16, 90.7% of patients achieved PASI 50, 79.1% achieved PASI 75, and 46.5% attained PASI 90. There was also a decrease in mean BSA and CDLQI values to 3.5 ± 3.8 and 5.4 ± 5.7, respectively. Conclusions: Etanercept proved to be effective, safe, and well-tolerated among the paediatric population with psoriasis.
